van de Putte, L. B. A., Rau, R., Breedveld, F., Kalden, J., Malaise, M., van Riel, P. L. C. M., . . . Kupper, H. (2003). Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: A 12 week, phase II study.
Citação norma Chicagovan de Putte, L B A., et al. Efficacy and Safety of the Fully Human Anti-tumour Necrosis Factor α Monoclonal Antibody Adalimumab (D2E7) in DMARD Refractory Patients With Rheumatoid Arthritis: A 12 Week, Phase II Study. 2003.
MLA引文van de Putte, L B A., et al. Efficacy and Safety of the Fully Human Anti-tumour Necrosis Factor α Monoclonal Antibody Adalimumab (D2E7) in DMARD Refractory Patients With Rheumatoid Arthritis: A 12 Week, Phase II Study. 2003.